Download PDF
CC BY 4.0 · TH Open 2021; 05(03): e335-e337
DOI: 10.1055/s-0041-1732342
Case Report

Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine

Katerina Pavenski 
1   Department of Medicine and Laboratory Medicine, St. Michael's Hospital – Unity Health Toronto, Toronto, Canada
2   Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, Canada
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints
Zoom Image

Abstract

An 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroids and rituximab and subsequently recovered. This case report highlights the need to monitor patients with iTTP following vaccination.

Keywords

ADAMS/ADAMTS 13 - thrombotic thrombocytopenic purpura (TTP / HUS) - thrombocytopenia


Publication History

Received: 01 June 2021

Accepted: 18 June 2021

Article published online:
09 August 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany